fda declaratory order semaglutide shortage resolved GLP-1 Drugs: Removes from the Drug List FDA Ends Semaglutide Shortage Listing,

As production struggles to keep up, the pharma industry is now focusing on the upcoming patent expiry of key GLP-1 drugs like semaglutide, expected to start in early 2026 in countries like India, Brazil, China, and Canada (some reports even suggest 2025)

By slowing digestion and increasing feelings of fullness, semaglutide is also effective in reducing body weight

The dietary recommendations that accompany most genetic reports are based on conventional nutrition frameworks and may not be appropriate for women with lipoedema following a therapeutic carbohydrate reduction approach

PlexusDx partners with licensed providers to integrate genetic and compounded medication options, supporting deeper personalization beyond standard telehealth models

Market Applications and Commercial Opportunities The biopharmaceutical industry recognizes critical commercial potential for progressed metabolic treatments